January 1, 1993Cancer Investigation
An Intensive Sequenced Adjuvant Chemotherapy Regimen for Breast Cancer
Why the study?
Does an intensive sequenced adjuvant chemotherapy regimen (CMFVP followed by doxorubicin) improve disease-free survival and have acceptable toxicity in women with node-positive, stage II breast carcinoma?
Population
22 women (17 pre- and 5 postmenopausal) with node-positive, stage II breast carcinoma
Design
Case_series
Follow-up
median 43 months (range: 20-89 months)
Authors
Discussion
Loading...
Member takes
Implication
Should not change practice; hypothesis-generating for sequenced adjuvant regimens in node-positive breast cancer.
Structured PICO
Does an intensive sequenced adjuvant chemotherapy regimen (CMFVP followed by doxorubicin) improve disease-free survival and have acceptable toxicity in women with node-positive, stage II breast carcinoma?
P
Population
22 women (17 pre- and 5 postmenopausal) with node-positive, stage II breast carcinoma
I
Intervention
Adjuvant chemotherapy consisting of 16 weeks of intensive CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) followed by four monthly, 3-day cycles of escalating doxorubicin
O
Outcome
Disease-free survival and toxicityhard clinical
Adjuvant CMFVP followed by intensive doxorubicin is feasible and yields an 80.5% chance of disease-free survival at 42 months in women with node-positive stage II breast cancer.
Cite This Study
Bhardwaj et al. (1993) studied this question.